NORTH CHICAGO, Ill.,
April 7, 2021 /PRNewswire/ -- AbbVie
(NYSE: ABBV) today announced new data from its expansive
neuroscience portfolio will be presented at the 2021 American
Academy of Neurology (AAN) Annual Meeting, to be held virtually
from April 17-22. A total of 33
abstracts, including one podium presentation during the Clinical
Trials Plenary Session and three oral presentations, will be shared
from a broad range of studies across the spectrum of migraine,
advanced Parkinson's disease and spasticity.
"Our strong presence at AAN reflects our expanded portfolio of
approved and investigational treatments designed to address a wide
range of complicated, often debilitating neurological disorders,"
said Michael Gold, M.D., vice
president, neuroscience development, AbbVie. "We look forward to
sharing our progress in a number of areas, including pivotal Phase
3 data in migraine, with the goal of making a remarkable impact on
patients' lives."
Researchers will present data from several studies on migraine,
including new findings on atogepant, AbbVie's investigational
preventive treatment of migraine in adults who meet criteria for
episodic migraine as well as results evaluating the efficacy
and safety of BOTOX® (onabotulinumtoxinA)
and UBRELVY® (ubrogepant).
In addition, investigators will present the study design of the
Phase 3 study assessing the efficacy and safety of the
investigational treatment ABBV-951 (foslevodopa/foscarbidopa), a
levodopa/carbidopa prodrug administered as a 24-hour continuous,
subcutaneous infusion in people with advanced Parkinson's
disease.
Key AbbVie abstracts and presentation details for the 2021 AAN
Annual Meeting program are outlined below. Posters will be
available during and for 30 days following the meeting.
Abstract
Title
|
Presentation
Details
All times
CT
|
Migraine
|
Atogepant
Significantly Reduces Mean Monthly Migraine Days in the Phase 3
Trial (ADVANCE) for the Prevention of Migraine
|
Clinical Trials
Plenary Session
Tuesday, April
20
9:15 a.m.
CT
|
Long-term Safety and
Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1
year for the Preventive Treatment of Migraine
|
S5: Headache
1
Saturday, April
17
3 p.m. CT
|
Atogepant Improved
Patient-Reported Migraine-Specific Quality of Life in a 12-Week
Phase 3 (ADVANCE) Trial for Preventive Treatment of
Migraine
|
Poster
|
Atogepant Improved
Patient-Reported Outcome (PRO) Measures of Activity Impairment in
Migraine-Diary and Headache Impact Test in a 12-Week, Double-blind,
Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of
Migraine
|
Poster
|
Ubrogepant Was Safe
and Well Tolerated in the Acute Treatment of Perimenstrual
Migraine
|
S5: Headache
1
Saturday, April
17
3:32 p.m.
CT
|
Assessing Barriers to
Care in Episodic and Chronic Migraine: Results From the Chronic
Migraine Epidemiology and Outcomes (CaMEO) Study
|
S15: Headache
2
Monday, April
19
1:32 p.m.
CT
|
Characterizing
Preventive Treatment Gaps in Migraine: Results from the CaMEO
Study
|
Poster
|
Real-World Evidence
for Control of Chronic Migraine (CM) in Patients Meeting American
Headache Society (AHS) Criteria Who Received Calcitonin
Gene‒Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to
OnabotulinumtoxinA Treatment
|
Poster
|
Real-World Evidence
for Control of Patients With Chronic Migraine Who Received CGRP
Monoclonal Antibody Therapy Added to OnabotulinumtoxinA
Treatment
|
Poster
|
Consecutive
Headache-Free Days With OnabotulinumtoxinA Treatment in Patients
With Chronic Migraine: A Pooled PREEMPT Analysis
|
Poster
|
Real-World Safety and
Efficacy of 155-195U OnabotulinumtoxinA in Participants With
Chronic Migraine: Results From the REPOSE Study
|
Poster
|
Advanced
Parkinson's Disease
|
Efficacy and Safety
of Subcutaneous Foslevodopa/Foscarbidopa Versus Oral
Levodopa/Carbidopa in Advanced Parkinson's Disease Patients: Design
of a Phase 3, Randomized, Double-blind, Double-dummy, Active
Controlled 12-Week Trial
|
Poster
|
Identifying Care Gaps
in Parkinson's Disease Patients Eligible for Device-Aided
Therapies: Results from Using the MANAGE-PD Tool in Patients from
G7 Countries
|
Poster
|
Unmet Needs and
Treatment Patterns of Advanced Parkinson's Disease Patients in the
United States
|
Poster
|
A Retrospective Study
Evaluating the Use of Anti-Parkinsonian Medications in Patients
with Advanced Parkinson's Disease Who Are Treated with
Levodopa-Carbidopa Intestinal Gel and Deep Brain Stimulation: The
PD-DUAL Study
|
Poster
|
Sustained
Improvements in Motor and Non-Motor Symptoms in Advanced
Parkinson's Disease Patients Treated with Carbidopa Levodopa
Enteral Suspension in a 'Real-World' Study: Interim Results of the
Multinational DUOGLOBE Study With at least 24 Months
Follow-Up
|
Poster
|
Spasticity
|
Consistent Dosing
Over Time and Within Treatment Interval Groups with
OnabotulinumtoxinA: Analysis from the Adult Spasticity
International Registry (ASPIRE)
|
Poster
|
A full list of all 33 AbbVie abstracts accepted for presentation
at the 2021 AAN Annual Meeting can be found here.
About Atogepant
Atogepant is an investigational orally
administered, CGRP receptor antagonist (gepant) specifically
developed for the preventive treatment of migraine. CGRP and its
receptors are expressed in regions of the nervous system associated
with migraine pathophysiology. Studies have shown that CGRP levels
are elevated during migraine attacks and selective CGRP receptor
antagonists confer clinical benefit in migraine.
The U.S. Food and Drug Administration (FDA) has accepted the New
Drug Application (NDA) for atogepant. AbbVie anticipates a
regulatory decision in late Q3 2021.
About ABBV-951
ABBV-951 (foslevodopa/foscarbidopa) is a continuous subcutaneous
infusion being investigated for the treatment of advanced
Parkinson's disease.
About
BOTOX®
BOTOX® was first
approved by the FDA in 1989 for two rare eye muscle disorders –
blepharospasm and strabismus in adults. Today,
BOTOX® is FDA-approved for 12 therapeutic indications,
including Chronic Migraine, overactive bladder, leakage of urine
(incontinence) due to overactive bladder caused by a neurologic
condition in adults, cervical dystonia, adult and pediatric
spasticity, severe underarm sweating (axillary hyperhidrosis), and
pediatric detrusor overactivity associated with a neurologic
condition.
BOTOX® (onabotulinumtoxinA)
Important Information
Indications
BOTOX® is
a prescription medicine that is injected into muscles
and used:
- To treat overactive bladder symptoms such as a strong need to
urinate with leaking or wetting accidents (urge urinary
incontinence), a strong need to urinate right away (urgency), and
urinating often (frequency) in adults 18 years and older when
another type of medicine (anticholinergic) does not work well
enough or cannot be taken
- To treat leakage of urine (incontinence) in adults 18 years and
older with overactive bladder caused by a neurologic disease who
still have leakage or cannot tolerate the side effects after trying
an anticholinergic medication
- To treat overactive bladder due to a neurologic disease in
children 5 years of age and older when another type of medicine
(anticholinergic) does not work well enough or cannot be taken
- To prevent headaches in adults with chronic migraine who have
15 or more days each month with headache lasting 4 or more hours
each day in people 18 years or older
- To treat increased muscle stiffness in people 2 years of age
and older with spasticity
- To treat the abnormal head position and neck pain that happens
with cervical dystonia (CD) in people 16 years and older
- To treat certain types of eye muscle problems (strabismus) or
abnormal spasm of the eyelids (blepharospasm) in people 12 years of
age and older
BOTOX® is
also injected into the skin to treat the symptoms
of severe underarm sweating (severe
primary axillary hyperhidrosis) when medicines
used on the skin (topical) do not work
well enough in people 18 years
and older.
It is not known whether
BOTOX® is safe and
effective to prevent headaches in
patients with migraine
who have 14 or fewer headache days
each month (episodic migraine).
BOTOX® has not been shown to help people perform task-specific
functions with their upper limbs or
increase movement in joints that are
permanently fixed in position by stiff muscles.
It is not known whether BOTOX® is
safe and effective for severe sweating anywhere other
than your armpits.
IMPORTANT SAFETY INFORMATION
BOTOX® may cause
serious side effects that can
be life threatening. Get medical help right
away if you
have any of these problems any time (hours
to weeks) after injection
of BOTOX®:
- Problems swallowing, speaking, or breathing, due to
weakening of associated muscles, can be severe and result in loss
of life. You are at the highest risk if these problems are
pre-existing before injection. Swallowing problems may last for
several months
- Spread of toxin effects. The effect of botulinum toxin
may affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, and trouble swallowing
There has not been a confirmed serious case of spread of toxin
effect away from the injection site when BOTOX® has been
used at the recommended dose to treat chronic migraine, severe
underarm sweating, blepharospasm, or strabismus.
BOTOX® may cause loss of strength or general muscle
weakness, vision problems, or dizziness within hours to weeks of
taking BOTOX®. If this happens, do not drive a car,
operate machinery, or do other dangerous activities.
Do not receive BOTOX® if you: are
allergic to any of the ingredients in BOTOX® (see
Medication Guide for ingredients); had an allergic reaction to any
other botulinum toxin product such as Myobloc®
(rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin infection at
the planned injection site.
Do not receive BOTOX® for the treatment of
urinary incontinence if you: have a urinary tract infection
(UTI) or cannot empty your bladder on your own and are not
routinely catheterizing. Due to the risk of urinary retention (not
being able to empty the bladder), only patients who are willing and
able to initiate catheterization post treatment, if required,
should be considered for treatment.
Patients treated for overactive bladder:
In clinical trials, 36 of the 552 patients had to self-catheterize
for urinary retention following treatment with BOTOX®
compared to 2 of the 542 treated with placebo. The median duration
of post-injection catheterization for these patients treated with
BOTOX® 100 Units (n = 36) was 63 days (minimum 1 day to
maximum 214 days) as compared to a median duration of 11 days
(minimum 3 days to maximum 18 days) for patients receiving placebo
(n = 2). Patients with diabetes mellitus treated with
BOTOX® were more likely to develop urinary retention
than nondiabetics.
Adult Patients treated for overactive bladder due to
neurologic disease:
In clinical trials, 30.6% of patients (33/108) who were not using
clean intermittent catheterization (CIC) prior to injection,
required catheterization for urinary retention following treatment
with BOTOX® 200 Units as compared to 6.7% of patients
(7/104) treated with placebo. The median duration of post-injection
catheterization for these patients treated with BOTOX®
200 Units (n = 33) was 289 days (minimum 1 day to maximum 530 days)
as compared to a median duration of 358 days (minimum 2 days to
maximum 379 days) for patients receiving placebo (n = 7). Among
patients not using CIC at baseline, those with MS were more likely
to require CIC post injection than those with SCI.
The dose of BOTOX® is not the same as, or
comparable to, another botulinum toxin product.
Serious and/or immediate allergic reactions have been
reported, including itching, rash, red itchy welts, wheezing,
asthma symptoms, dizziness, or feeling faint. Get medical help
right away if you experience symptoms; further injection of
BOTOX® should be discontinued.
Tell your doctor about all your muscle or nerve
conditions, such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton
syndrome, as you may be at increased risk of serious side effects,
including difficulty swallowing and difficulty breathing from
typical doses of BOTOX®.
Tell your doctor if you have any breathing-related
problems. Your doctor may monitor you for breathing problems
during treatment with BOTOX® for spasticity or for
detrusor overactivity associated with a neurologic condition. The
risk of developing lung disease in patients with reduced lung
function is increased in patients receiving BOTOX®.
Cornea problems have been reported. Cornea (surface of
the eye) problems have been reported in some people receiving
BOTOX® for their blepharospasm, especially in people
with certain nerve disorders. BOTOX® may cause the
eyelids to blink less, which could lead to the surface of the eye
being exposed to air more than is usual. Tell your doctor if you
experience any problems with your eyes while receiving
BOTOX®. Your doctor may treat your eyes with drops,
ointments, contact lenses, or with an eye patch.
Bleeding behind the eye has been reported. Bleeding
behind the eyeball has been reported in some people receiving
BOTOX® for their strabismus. Tell your doctor if you
notice any new visual problems while receiving
BOTOX®.
Bronchitis and upper respiratory tract infections (common
colds) have been reported. Bronchitis was reported more
frequently in adults receiving BOTOX® for upper limb
spasticity. Upper respiratory infections were also reported more
frequently in adults with prior breathing-related problems with
spasticity. In pediatric patients treated with BOTOX®
for upper limb spasticity, upper respiratory tract infections were
reported more frequently. In pediatric patients treated with
BOTOX® for lower limb spasticity, upper respiratory
tract infections were not reported more frequently than
placebo.
Autonomic dysreflexia in patients
treated for overactive bladder due to neurologic disease.
Autonomic dysreflexia associated with intradetrusor injections of
BOTOX® could occur in patients treated for detrusor
overactivity associated with a neurologic condition and may require
prompt medical therapy. In clinical trials, the incidence of
autonomic dysreflexia was greater in adult patients treated with
BOTOX® 200 Units compared with placebo (1.5% versus
0.4%, respectively).
Tell your doctor about all your medical conditions, including
if you: have or have had bleeding problems; have plans to have
surgery; had surgery on your face; weakness of forehead muscles;
trouble raising your eyebrows; drooping eyelids; any other abnormal
facial change; have symptoms of a urinary tract infection (UTI) and
are being treated for urinary incontinence (symptoms of a urinary
tract infection may include pain or burning with urination,
frequent urination, or fever); have problems emptying your bladder
on your own and are being treated for urinary incontinence; are
pregnant or plan to become pregnant (it is not known
if BOTOX® can harm your unborn baby); are
breastfeeding or plan to (it is not known if BOTOX®
passes into breast milk).
Tell your doctor about all the medicines you take,
including prescription and over-the-counter medicines, vitamins,
and herbal supplements. Using BOTOX® with certain other
medicines may cause serious side effects. Do not start any new
medicines until you have told your doctor that you have received
BOTOX® in the past.
Tell your doctor if you received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such as Myobloc®,
Dysport®, or Xeomin® in the
past (tell your doctor exactly which product you received); have
recently received an antibiotic by injection; take muscle
relaxants; take an allergy or cold medicine; take a sleep medicine;
take aspirin-like products or blood thinners.
Other side effects of BOTOX® include:
dry mouth, discomfort or pain at the injection site, tiredness,
headache, neck pain, eye problems: double vision, blurred vision,
decreased eyesight, drooping eyelids, swelling of your eyelids, dry
eyes; drooping eyebrows; and upper respiratory tract infection. In
adults being treated for urinary incontinence, other side effects
include urinary tract infection and painful urination. In children
being treated for urinary incontinence, other side effects include
urinary tract infection and bacteria in the urine. If you have
difficulty fully emptying your bladder on your own after receiving
BOTOX®, you may need to use disposable self-catheters to
empty your bladder up to a few times each day until your bladder is
able to start emptying again.
For more information refer to the Medication Guide or talk with
your doctor.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
Please see BOTOX® full
Product Information, including Boxed
Warning and Medication Guide.
About UBRELVY® (ubrogepant)
UBRELVY® (ubrogepant) is an orally administered
calcitonin gene-related peptide (CGRP) receptor antagonist (gepant)
for the acute treatment of migraine with or without aura in adults
that is an option for a wide range of patients who experience
migraine attacks. UBRELVY® is the first pill of its kind
to directly block CGRP, a protein released during a migraine
attack, from binding to its receptors.
IMPORTANT SAFETY INFORMATION
Who should not take UBRELVY® (ubrogepant)?
Do not take UBRELVY® if you are taking medicines known
as strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin,
itraconazole.
What should I tell my healthcare provider before taking
UBRELVY®?
Tell your healthcare provider about all your medical conditions,
including if you:
- Have liver problems
- Have kidney problems
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements. Your healthcare provider can tell
you if it is safe to take UBRELVY® with other
medicines.
What are the most common side effects of
UBRELVY®?
The most common side effects are nausea (4%) and sleepiness (3%).
These are not all of the possible side effects of
UBRELVY®.
What is UBRELVY® (ubrogepant)?
UBRELVY® is a prescription medicine used for the acute
treatment of migraine attacks with or without aura in adults.
UBRELVY® is not used to prevent migraine headaches.
Please see full
Prescribing Information.
About DUOPA
DUOPA (carbidopa and levodopa) enteral suspension is a prescription
medicine used for treatment of advanced Parkinson's disease. DUOPA
contains two medicines: carbidopa and levodopa.
Important Safety Information
What is the most important safety information I should know
about DUOPA?
- Stomach and intestine (gastrointestinal) problems and
problems from the procedure you will need to have to receive DUOPA
(gastrointestinal procedure-related problems) may occur. Some
of these problems may require surgery and may lead to death.
-
- Serious side effects may include: a blockage of your
stomach or intestines (bezoar); stopping movement through
intestines (ileus); drainage, redness, swelling, pain, feeling of
warmth around the small hole in your stomach wall (stoma); bleeding
from stomach ulcers or your intestines; inflammation of your
pancreas (pancreatitis); infection in your lungs (pneumonia); air
or gas in your abdominal cavity; skin infection around the
intestinal tube, pocket of infection (abscess), or infection in
your blood (sepsis) or abdominal cavity may occur after surgery;
stomach pain, nausea, or vomiting.
- Tell your healthcare provider right away if you have any of the
following symptoms of stomach and intestine problems and
gastrointestinal procedure-related problems: stomach (abdominal)
pain; constipation that does not go away; nausea or vomiting;
fever; blood in your stool; or a dark tarry stool.
Your healthcare provider will talk to you about the stoma
procedure. Before the stoma procedure, tell your healthcare
provider if you ever had a surgery or problems with your
stomach.
Talk to your healthcare provider about what you need to do to
care for your stoma. After the procedure, you and your
healthcare provider will need to regularly check the stoma for any
signs of infection.
Do not take DUOPA if you currently take or have recently
taken (within 2 weeks) a medication for depression called a
non-selective monoamine oxidase (MAO) inhibitor. Ask your
healthcare provider or pharmacist if you are not sure if you take
an MAO inhibitor.
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements. Using DUOPA with certain
other medicines, including medications for high blood pressure, MAO
inhibitors, antipsychotics, metoclopramide, isoniazid, and iron or
vitamin supplements, may cause serious side effects. High-protein
foods may affect how DUOPA works. Tell your healthcare provider if
you change your diet.
DUOPA may cause serious side effects. Talk to your doctor
before starting DUOPA and while on DUOPA if you have had or have
any of these:
- Falling asleep during normal daily activities without
warning. DUOPA may cause you to fall asleep while you are doing
daily activities such as driving, which may result in an accident.
This can happen as late as one year after starting DUOPA. Do
not drive or operate machinery until you know how DUOPA affects
you. Tell your healthcare provider if you take medicines that can
make you sleepy, such as sleep medicines, antidepressants, or
antipsychotics.
- Low blood pressure when you stand or sit up quickly.
After you have been sitting or lying down, stand up slowly to help
reduce dizziness, nausea, sweating, or fainting until you know how
DUOPA affects you.
- Seeing, hearing, or feeling things that are not real
(hallucinations).
- Unusual urges. Some people taking medicines for
Parkinson's disease, including DUOPA, have reported urges such as
excessive gambling, compulsive eating, compulsive shopping, and
increased sex drive.
- Depression and suicide. DUOPA can cause or worsen
depression. Pay close attention to changes in your mood, behavior,
thoughts, or feelings. Call your healthcare provider right away if
you feel depressed or have thoughts of suicide.
- Uncontrolled sudden movements (dyskinesia). If you have
new dyskinesia or your dyskinesia gets worse, tell your healthcare
provider. This may be a sign that your dose of DUOPA or other
Parkinson's medicines may need to be adjusted.
- Progressive weakness or numbness or loss of sensation
in the fingers or feet (neuropathy).
- Heart attack or other heart problems. Tell your
healthcare provider if you have experienced increased blood
pressure, a fast or irregular heartbeat, or chest pain.
- Abnormal blood tests. DUOPA may cause changes in certain
blood tests, especially certain hormone and kidney function blood
tests.
- Worsening of the increased pressure in your eyes
(glaucoma). The pressure in your eyes should be checked after
starting DUOPA.
Do not stop using DUOPA or change your dose unless you are
told to do so by your healthcare provider. Tell your healthcare
provider if you develop withdrawal symptoms such as fever,
confusion, or severe muscle stiffness.
The most common side effects of DUOPA include:
complications of tubing placement procedure, swelling of legs and
feet, nausea, high blood pressure (hypertension), depression, and
mouth and throat pain.
Please see the
full Prescribing Information including
Medication Guide for additional information about DUOPA.
About AbbVie Leadership in Migraine
AbbVie, a leader in the migraine space, markets BOTOX®
(onabotulinumtoxinA), the first FDA-approved, preventive treatment
for adults with Chronic Migraine and UBRELVY®
(ubrogepant), the first FDA-approved oral calcitonin gene-related
peptide (CGRP) receptor antagonist (gepant), which is indicated for
the acute treatment of migraine with or without aura in adults.
About AbbVie in Neuroscience
At AbbVie, our commitment
to preserve the personhood of those living with neurological and
psychiatric disorders is unwavering. Every challenge in this
uncharted territory makes us more determined and drives us harder
to discover and deliver solutions for patients, care partners and
clinicians. AbbVie's Neuroscience portfolio consists of approved
therapies and a robust pipeline in neurological and psychiatric
disorders, including Alzheimer's disease, bipolar I disorder, major
depressive disorder, migraine, Parkinson's disease, spinal cord
injuries, post-stroke spasticity, schizophrenia, stroke and
others.
We have a strong investment in neuroscience research, with our
Foundational Neuroscience Center in Cambridge, Massachusetts, and our Neuroscience
Discovery site in Ludwigshafen, Germany, where our research and resilience in
these challenging therapeutic areas is yielding a deeper
understanding of the pathophysiology of neurological and
psychiatric disorders, and identifying targets for potential
disease-modifying therapeutics aimed at making a difference in
people's lives.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @AbbVie on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered,
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. The words "believe," "expect,"
"anticipate," "project" and similar expressions, among others,
generally identify forward-looking statements. AbbVie cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, failure to
realize the expected benefits from AbbVie's acquisition of Allergan
plc ("Allergan"), failure to promptly and effectively integrate
Allergan's businesses, competition from other products, challenges
to intellectual property, difficulties inherent in the research and
development process, adverse litigation or government action,
changes to laws and regulations applicable to our industry and the
impact of public health outbreaks, epidemics or pandemics, such as
COVID-19. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2020 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
View original
content:http://www.prnewswire.com/news-releases/abbvie-to-present-data-across-its-robust-neuroscience-portfolio-at-the-2021-american-academy-of-neurology-aan-annual-meeting-301263600.html
SOURCE AbbVie